References
- Dailey AM, Tannock LR. Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep 2011;11:77-82
- Garg R, Johnston V, McNally PG, et al. U-500 insulin: why, when and how to use in clinical practice? Diabetes Metab Res Rev 2007;23:265-8
- Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-9
- Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract 2010;90:231-42
- Boldo A, Comi RJ. Clinical experience with U500 insulin: risks and benefits. Endocr Pract 2012;18:56-61
- Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol 2012;6:412-20
- Segal AR, Brunner JE, Burch FT, et al. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 2010;67:1526-35
- Ziesmer AE, Kelly KC, Guerra PA, et al. U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients. Endocr Pract 2012;18:34-8
- de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 2011;34:2496-501
- Ginde AA, Blanc PG, Lieberman RM, et al. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4
- Faries DE, Leon AC, Haro JM, et al. Analysis of observational health care data using SAS. Cary, NC: SAS Institute Inc, 2011
- D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
- Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-61
- Rosenbaum P. Design of observational studies. New York: Springer Inc., 2010
- Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25:2084-106
- Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-48
- Lee LJ, Li Q, Reynolds MW, et al. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe. J Med Econ 2011;14:75-86
- Maciejewski ML, Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 2004;27:B69-B73
- Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005;28:1240-4
- Eli Lilly and Company. Humulin R regular U-500 prescribing information. Eli Lilly and Co., http://pi.lilly.com/us/humulinr-u500-pi.pdf. Accessed January 21, 2013
- Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther 2010;27:94-104
- Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications 2012;26:399-406